Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Rheumatology Jurnal Mandala Pharmacon Indonesia
Joewono Soeroso
Medical Faculty Airlangga University/Dr. Soetomo Hospital, Surabaya
Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Systemic sclerosis and hyperthyroidism in pregnancy Awalia, Awalia; Yuliasih, Yuliasih; Soeroso, Joewono
Indonesian Journal of Rheumatology Vol 4, No 1 (2013)
Publisher : Indonesian Rheumatology Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (216.305 KB)

Abstract

Systemic sclerosis (SSc) is a connective tissue disease affecting women of childbearing age at least five times more than men. For a long time, pregnant women with SSc have high morbidity and mortality based on case reports and case series. Therefore, the disease was a contraindication for pregnancy. However, current retrospective studiesshow that despite of an increased frequency of prematurity and small for gestational age infants, overall maternal and neonatal survival is good. With close monitoring and appropriate therapy, most scleroderma patients can sustain a successful pregnancy.
The Use of Tocilizumab in Combination with Methotrexate in Indonesian Rheumatoid Arthritis Patients (PICTURE INA Study) Setyohadi, Bambang; Isbagio, Harry; Wachjudi, Rachmat Gunadi; Soeroso, Joewono; Kalim, Handono; Achadiono, Deddy Nur Wachid
Indonesian Journal of Rheumatology Vol 10, No 1 (2018)
Publisher : Indonesian Rheumatology Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (577.723 KB)

Abstract

Background Aim of this research is to assess the efficacy and safety of tocilizumab (TCZ) in combination with methotrexate (MTX) in Indonesian patients with moderate to severe active rheumatoid arthritis (RA) who have an inadequate response to non-biologic DMARDs.Methods This was a interventional, prospective, single arm, multicenter, study in  Indonesian male or female patients aged ≥ 18 years old, with a diagnosis of RA for > 6 months based on ACR 1987 revised criteria with moderate to severe disease activity (DAS28 score > 3.2) after ≥ 12 weeks of non-biologic DMARDs treatment. The treatment consisted of tocilizumab, 8 mg/kg, intravenous (IV), every 4 weeks for a total of 6 infusion in combination with oral MTX (10−25 mg) every week. Efficacy was assessed based on the percentage of patients achieving low disease activity state (DAS28 < 3.2), percentage of patients achieving reduction > 1.2 point of DAS28, percentage of patients achieving remission (DAS28 < 2.6), and percentage of patients with ACR20, ACR50, and ACR70 responses. Descriptive statistics will be used for presentation of results.Results 100% patients reached low disease activity (DAS28 ≤ 3.2) at last study visit (week 24) and clinically significant improvement (reduction at least 1.2 units) at every visit in DAS28, both for ITT or PP patients. Remission (DAS28 < 2.6) was observed in 82.1% (ITT patients) and 93.1 % (PP patients) on last study visit. ACR20, ACR50, and ACR70 were achieved in 20%, 34%, and 34% (ITT patients), and 7%, 24%, and 62% (PP patients) on week 24. There were 3 out of 39 patients (7.69%) with adverse events (AE) and serious adverse events (SAE) that resulted in discontinuation of TCZ treatment, consisting of 1 patient with SAE of sepsis ec acquired community pneumonia, 1 patient with SAE of pneumonia tuberculosis, and 1 patient with AE of candidiasis. Most common adverse events were hepatic dysfunction (30.7%), hypercholesterolemia (23.1%), followed by arthralgia (20.5%) Twelve percent of patients needed dose modification due to elevated liver enzyme (elevated ALT/SGPT level).Conclusion Tocilizumab seems to be efficacious and likely to have good safety profile in non- biologic DMARD nonresponsive RA patients of PICTURE INA study.   Keywords: Rheumatoid Arthritis, Tocilizumab, DMARD, DAS28
Pristane modulates specific changes on T cell dependent pathway of lupus in non-F1 BALB/c mice Indriyanti, Niken; Arifianti, Lusiana; Soeroso, Joewono; Khotib, Junaidi
Jurnal Mandala Pharmacon Indonesia Vol. 10 No. 1 (2024): Jurnal Mandala Pharmacon Indonesia Special Issue for 18th Mulawarman Pharmaceu
Publisher : Program Studi Farmasi Universitas Mandala Waluya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35311/jmpi.v10i1.533

Abstract

Animal modeling for lupus is a crucial step in the process of discovering efficacious drugs. There are many drug candidates that have potential benefits for the treatment of lupus, but finding an appropriate model remains challenging. The appropriate model based on the literature is an induction model that uses 2,6,10,14 tetramethylpentadecane (TMPD) in female Balb/c mice. The TMPD increases the probability of damage beyond lupus, to the joint and kidneys. Therefore, the purpose of this study was to develop a lupus model by TMPD to test a drug candidate. The experimental method was measuring many biomarkers involved in the TMPD mechanism to obtain lupus-like disease mice. We measured CD4+CD25+FOXP3+ and CD4+CD62L+ T-regs, CD123+IFN-?+ dendritic cells (flow cytometry); total leukocytes (Turk staining); anti-Sm antibody (ELISA); and renal and joint histology (HE staining). After the 6th month, there were reduction (p<0.05) of the T regulatory percentage of CD4+CD25L+ T cells (Naïve=19.39±3.06%, TMPD-treated=5.72±3.43%) and CD25+FOXP3 + T cells (Naïve=10.32±4.47%, TMPD-treated=7.70±4.47%), meanwhile, the IFN-? increased significantly (p<0.05), (Naïve=6.92±8.67%, TMPD-treated=11.42±0.95%), and the total leukocytes increased (p<0.05) (Naïve=9,800±1,698, TMPD-treated=17,500±1,490 cells/mm3). The anti-Sm antibody was also present in the TMPD-treated mice as one cause which led to renal and joint structural disorders. The biomarkers were analyzed by using Independent T-test, so this positive lupus model with its tested biomarkers is valid and can be used to test drugs for lupus.
Co-Authors Arifianti, Lusiana Awalia, Awalia Awalia, Awalia Bambang Setyohadi Deddy Nur Wachid Achadiono Handono Kalim Harry Isbagio HENDRA GUNAWAN B11211055 Indriyanti, Niken Junaidi Khotib Rachmat Gunadi Wachjudi Yundari, Yundari